Alemtuzumab shows further benefits over INF-β-1b for RRMS

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1657, 2008-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Interferon (INF)-β-1b has a beneficial impact on MRI efficacy measures regarding lesion activity in patients with newly diagnosed multiple sclerosis

By  

Inpharma, Vol. 1, Iss. 1611, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Interferon (IFN)- -1a shows comparable efficacy to IFN- -1b in patients with RRMS

By  

Inpharma, Vol. 1, Iss. 1318, 2001-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Further findings for interferon-beta-1a in RRMS

By  

Inpharma, Vol. 1, Iss. 1657, 2008-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Alemtuzumab/interferon-β-1a: Immune thrombocytopenia: 7 case reports

By  

Reactions Weekly, Vol. 1, Iss. 1389, 2012-01 ,pp. : 7-8

Adis International

Access to resources Recommend Favorite

. . . and also shows QOL benefits

By  

Inpharma, Vol. 1, Iss. 1661, 2008-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite